Adtran brings its latest coherent innovation to OFCnet multi-vendor demo
7.3.2023 16:00:00 EET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of open and disaggregated networking solutions, today announced that its latest coherent innovation will be showcased at OFC as part of OFCnet. The demo reveals how the Adtran FSP 3000 open line system (OLS) can bring new levels of flexibility to optical networks by enabling optimized, tailored spectrum services. In collaboration with Acacia, Cisco, Coherent Corp., Corning, EXFO, Nokia and VIAVI Solutions, Adtran will showcase 100ZR, 200Gbit/s, 400Gbit/s OpenZR+ and 800Gbit/s connectivity. The FSP 3000 DCI OLS is also playing a key role in the OIF 400ZR demo at OFC.
“Our demo shows how the spectrum-as-a-service concept has the potential to revolutionize the way operators utilize their fiber resources. It highlights how it’s possible to slice up the network even in a metro environment. With fully flexible spectrum allocation, operators can provide a wide variety of differentiated services and ensure they leverage the full capacity of their infrastructure. Not only will this help tackle ever-increasing data demand, but it also offers a new route to revenue growth,” said Jörg-Peter Elbers, head of advanced technology at Adtran. “Our compact FSP 3000 OLS is the key to realizing the full benefits of this open and flexible approach. It removes the limits of fixed channel grids so that untapped spectrum can be put to work.”
The coherent innovation demo features a three-node ring network with flexgrid ROADMs in the Adtran, Coherent Corp. and OFCnet booths. Adtran’s FSP 3000 OLS is used to ensure strict separation between users while minimizing the unused bandwidth between their spectrum services, and its high-resolution flexgrid ROADMs provide optical channel monitoring, demarcation and passband optimization for all spectrum services. Also on display is the Adtran TeraFlex™ CoreChannel™, which transports 100Gbit/s and 400Gbit/s Ethernet client signals over a coherent 800Gbit/s signal. In combination with Adtran’s MicroMux™, the terminal shows the transmission of 10Gbit/s services without any footprint increase. What’s more, Adtran’s OpenFabric+™ is being used to demonstrate 200Gbit/s connectivity.
“One of the most exciting elements of this demo is showcasing the value of our Coherent 100ZR. To meet growing traffic demands, network operators need to upgrade their edge aggregation infrastructure to support 100Gbit/s rates. However, this can be a costly and complex process. With its QSFP28 form factor, our Coherent 100ZR easily fits into existing host platforms and can operate over any optical network infrastructure. This facilitates the adoption of 100Gbit/s coherent technology at the network edge without major infrastructure changes and at an affordable price,” commented Ross Saunders, GM of Optical Engines, Adtran. “With a new purpose-built DSP, a standards-compliant QSFP28 form factor, and 5W power consumption, our Coherent 100ZR opens the door to widespread rollout of 100Gbit/s coherent technology at the optical edge.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005685/en/
Contact information
Published by
Adtran, Inc.
www.adtran.com
For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors
Rhonda Lambert
t +1 256-963-7450
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom